Maxi-Fen-10, ist ein guter Inhibitor der Prozesse, die die Regeneration von Testosteron in Östrogen, Blockierung der peripheren Östrogen-Rezeptoren. Gemäß der chemischen Zusammensetzung ist und ist Maxi-Fen-10 eine Derivatkonfiguration von Triphenylethylen. Dieses Medikament gehört zur Klasse der Sexualhormone. Es wurde für den Einsatz in der Medizin geschaffen, um die Gesundheit und Tamoxifen von Brustkrebs und anderen Krebsarten in einer schwachen Hälfte der Menschheit zu erhalten.
Dosing and Administration
Tablets are given inside without chewing, with a small amount of water. If two or more tablets are prescribed per day, they can be taken in one or two doses.
The recommended daily dose of tamoxifen for adults is 20 mg. In the case of widespread forms of the disease, the doses may be increased to 30-40 mg per day. The maximum daily dose of tamoxifen is 40 mg. Objectively, the effect of therapy is usually observed after 4-10 weeks of treatment, but in the case of metastases in the bones, the effect can be observed only after several months of treatment.
The duration of treatment with tamoxifen is determined by the severity and course of the disease. Usually treatment is lengthy. “
In the treatment of elderly patients or patients with impaired liver or kidney function, dose adjustment is not required.
Disorders from the blood system: rarely – thrombocytopenia (the number of platelets decreases to 80,000 – 90,000 / mm3), leukopenia; Very rarely – neutropenia, pancytopenia. Impaired vision: visual acuity, retinopathy, keratopathy, cataract. These effects probably depend on the doses and duration of therapy and can be partially reversible after cessation of tamoxifen treatment.
Endocrine disorders: due to the antiestrogenic effects of tamoxifen, undesirable side effects such as hot flashes, abnormal vaginal bleeding, menstrual irregularities, vaginal discharge, and itching of the sexual organs are most often noted. Also, possible fluid retention in the body, nausea, vomiting. Less often are transitory acceleration of tumor growth, dizziness, skin rash, fatigue, headache. In men, impotence or loss of libido is possible. In isolated cases, anorexia, dyspnoea, constipation, diarrhea, convulsions of the legs, depression, alopecia, or intense hair growth are observed. In premenopausal women, it is possible to stop menstruation, as well as sometimes reversible cystic ovarian edema. In a small number of patients with bone metastases, hypercalcemia develops at the onset of therapy. Perhaps an initial increase in pain in the bones and tumors, as well as the spread of erythema around the skin lesions, which may be evidence of the presence of terrains
Singing effect. It is also possible to increase existing skin lesions or the appearance of new ones.
Benign and malignant neoplasms with terapyatemoxifen are associated with an increased risk of proliferative changes in the endometrium, in particular, endometrial hyperplasia, polyps, endometriosis and, in rare cases, endometrial cancer. The likelihood of developing endometrial cancer increases with increasing duration of tamoxifen therapy and approximately 2 to 3 times the likelihood of endometrial cancer in women who have not received the drug. However, the clinical benefit of using tamoxifen in the treatment of breast cancer in women exceeds the possible risk of development of neoplastic endometrial structures.
Vascular disorders: often enough – thrombosis; Very rarely – pulmonary embolism. With the parallel use of tamoxifen and cytotoxic drugs, the risk of thromboembolic complications increases.
Disorders from the immune system: rarely – hypersensitivity reactions, including skin rash, angioedema, polymorphic erythema, Stevens-Johnson syndrome, bullous pemphigoid.
Disorders of the hepatobiliary system: impairment of hepatic enzyme activity; In isolated cases – fatty infiltration of the liver, cholestasis, hepatitis.
Most of the reported side effects are reversible and can be reduced or eliminated by decreasing the dose.